Saturday 17 October 2026
Export VBIO’s income statement to Excel — free account
Valion Bio, Inc.
VBIO Healthcare Biotechnology
Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023. In the quarter to June 2026, revenue grew 15.9%, EPS was flat and free cash flow fell 189.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.17
0.06
−4.88%
Follow VBIO
Valion Bio, Inc. (VBIO) P/E ratio
Valion Bio, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 34.2× (October 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2025 | 31.5× | — |
| Jun 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| 17 more quarters | Free account |
Against its own ten years
Low 0.0×
High 34.2×
Ten-year median
0.0×
Current reading's percentile
85
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MTNB Matinas Biopharma Holdings, Inc. compare | n/m |
| VBIO Valion Bio, Inc. | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| NTBLQ Notable Labs, Ltd. compare | n/m |
| ELAB PMGC Holdings Inc. compare | n/m |
| BPTSY Biophytis SA Sponsored ADR compare | n/m |
| EIGRQ Eiger BioPharmaceuticals, Inc. compare | n/m |
| BIORQ Biora Therapeutics, Inc. compare | n/m |
| WINT Windtree Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)